Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein

Journal of Biotechnology

Volumn 146, Issue 1-2, 2010, Pages 84-91

  Boado, Ruben J ^a,b   Hui, Eric Ka Wai ^a   Lu, Jeff Zhiqiang ^a   Zhou, Qing Hui ^b   Pardridge, William M ^b  

^a ArmaGen Technologies Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Decoy receptor; Delivery systems; Tumor necrosis factor

Indexed keywords

BINDING ASSAYS; BLOOD-BRAIN BARRIER; BRAIN DISORDERS; CHO CELL; DELIVERY SYSTEMS; EXTRACELLULAR DOMAINS; FUSION PROTEINS; HUMAN TUMORS; IN-VIVO; INSULIN RECEPTORS; MONOCLONAL ANTIBODIES (MAB); RHESUS MONKEY; TROJAN HORSE; TUMOR NECROSIS FACTORS; WESTERN BLOTTING;

BLOOD; CHROMATOGRAPHIC ANALYSIS; ELECTROPHORESIS; GLYCOPROTEINS; MACROPHAGES; MONOCLONAL ANTIBODIES; SIZE EXCLUSION CHROMATOGRAPHY; TUMORS;

PROTEINS;

ETANERCEPT; HYBRID PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; INSULIN RECEPTOR; INSULIN RECEPTOR ANTIBODY; INSULIN RECEPTOR ANTIBODY TUMOR NECROSIS FACTOR DECOY RECEPTOR FUSION PROTEIN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BLOOD BRAIN BARRIER; CHO CELL; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG UPTAKE; ELECTROPHORESIS; FEMALE; FUSION GENE; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RADIOIODINATION; RAT; RHESUS MONKEY; STABLE TRANSFECTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BRAIN; BRAIN CHEMISTRY; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DELIVERY SYSTEMS; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN GAMMA-CHAINS; MACACA MULATTA; MICE; PROTEIN ENGINEERING; RECEPTOR, INSULIN; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS;

EQUIDAE; MACACA MULATTA; PRIMATES;

EID: 77249163613     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2010.01.011     Document Type: Article

References (26)

1. Boado R.J., and Pardridge W.M. Comparison of blood-brain barrier transport of GDNF and an IgG-GDNF fusion protein in the Rhesus monkey. Drug Metab. Dispos. 37 (2009) 2299-2304
2. Boado, R.J., Pardridge, W.M., in press. Genetic engineering of IgG-glucuronidase fusion proteins. J. Drug Target.
3. Boado R.J., Hui E.K., Lu J.Z., and Pardridge W.M. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J. Biotechnol. 144 (2009) 135-141
4. Boado R.J., Zhang Y., Zhang Y., and Pardridge W.M. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol. Bioeng. 96 (2007) 381-391
5. Boado R.J., Zhang Y., Zhang Y., and Pardridge W.M. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol. Bioeng. 97 (2007) 1376-1386
6. Chan K.F., Siegel M.R., and Lenardo J.M. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 13 (2000) 419-422
7. Coloma M.J., Lee H.J., Kurihara A., Landaw E.M., Boado R.J., Morrison S.L., and Pardridge W.M. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res. 17 (2000) 266-274
8. Davies B., and Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10 (1993) 1093-1095
9. Himmerich H., Fulda S., Linseisen J., Seiler H., Wolfram G., Himmerich S., Gedrich K., Kloiber S., Lucae S., Ising M., Uhr M., Holsboer F., and Pollmacher T. Depression, comorbidities and the TNF-alpha system. Eur. Psychiatry 23 (2008) 421-429
10. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J.P., Daly T., Wiegand S.J., Yancopoulos G.D., and Rudge J.S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 11393-11398
11. Hui E.K., Boado R.J., and Pardridge W.M. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier. Mol. Pharm. 6 (2009) 1536-1543
12. Knoblach S.M., Fan L., and Faden A.I. Early neuronal expression of tumor necrosis factor-alpha after experimental brain injury contributes to neurological impairment. J. Neuroimmunol. 95 (1999) 115-125
13. Marchand F., Tsantoulas C., Singh D., Grist J., Clark A.K., Bradbury E.J., and McMahon S.B. Effects of Etanercept and Minocycline in a rat model of spinal cord injury. Eur. J. Pain 13 (2009) 673-681
14. Nawashiro H., Martin D., and Hallenbeck J.M. Neuroprotective effects of TNF binding protein in focal cerebral ischemia. Brain Res. 778 (1997) 265-271
15. Pardridge W.M., and Boado R.J. Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm. Res. 26 (2009) 2227-2236
16. Pardridge W.M. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug. Chem. 19 (2008) 1327-1338
17. Pardridge W.M., Kang Y.S., Buciak J.L., and Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. 12 (1995) 807-816
18. Peppel K., Crawford D., and Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 174 (1991) 1483-1489
19. Plant S.R., Iocca H.A., Wang Y., Thrash J.C., O'Connor B.P., Arnett H.A., Fu Y.X., Carson M.J., and Ting J.P. Lymphotoxin beta receptor (Lt betaR): dual roles in demyelination and remyelination and successful therapeutic intervention using Lt betaR-Ig protein. J. Neurosci. 27 (2007) 7429-7437
20. Schlachetzki F., Zhu C., and Pardridge W.M. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J. Neurochem. 81 (2002) 203-206
21. Shohami E., Novikov M., Bass R., Yamin A., and Gallily R. Closed head injury triggers early production of TNF alpha and IL-6 by brain tissue. J. Cereb. Blood Flow Metab. 14 (1994) 615-619
22. Triguero D., Buciak J., and Pardridge W.M. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J. Neurochem. 54 (1990) 1882-1888
23. Tweedie D., Sambamurti K., and Greig N.H. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr. Alzheimer Res. 4 (2007) 378-385
24. Valesini G., Iannuccelli C., Marocchi E., Pascoli L., Scalzi V., and Di Franco M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun. Rev. 7 (2007) 35-41
25. Yepes M., Brown S.A., Moore E.G., Smith E.P., Lawrence D.A., and Winkles J.A. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am. J. Pathol. 166 (2005) 511-520
26. Zhang Y., and Pardridge W.M. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J. Neuroimmunol. 114 (2001) 168-172